Anaptysbio (ANAB) Cash from Investing Activities (QoQ) (2016 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Cash from Investing Activities (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.62 Bn | 1.34 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -52.40% |
| Dec 31, 2025 | -28.84% |
| Sep 30, 2025 | 183.72% |
| Jun 30, 2025 | 145.19% |
| Mar 31, 2025 | 150.51% |
| Dec 31, 2024 | -150.15% |
| Sep 30, 2024 | 2,500.49% |
| Jun 30, 2024 | -103.56% |
| Mar 31, 2024 | 39.53% |
| Dec 31, 2023 | 60.53% |
| Sep 30, 2023 | 249.77% |
| Jun 30, 2023 | -123.95% |
| Mar 31, 2023 | 297.25% |
| Dec 31, 2022 | 166.28% |
| Sep 30, 2022 | 54.32% |
| Jun 30, 2022 | 77.31% |
| Mar 31, 2022 | -369.18% |
| Dec 31, 2021 | -715.32% |
| Sep 30, 2021 | -71.45% |
| Jun 30, 2021 | -33.08% |